{"altmetric_id":15903666,"counts":{"readers":{"mendeley":18,"citeulike":0,"connotea":0},"total":{"posts_count":25},"news":{"unique_users_count":4,"unique_users":["oncology_nurse_advisor","pm_360","the_asco_post","pharmastar_italy"],"posts_count":10},"twitter":{"unique_users_count":14,"unique_users":["GarbineLizeaga","TheLancetOncol","elhadialgerino","ONKOSconsulting","duchongle","ClinicalBriefs","NHSResCornwall","FarmaOnco","hematosantpau","Sidnavigare","SCTNB","queizan","MartaCrespoHEM","lymphomahub"],"posts_count":14},"facebook":{"unique_users_count":1,"unique_users":["480798328659889"],"posts_count":1}},"selected_quotes":["Increased activity (and toxicity) of idelalisib + rituximab + bendamustine in R\/R CLL","Idelalisib + bendamustine + rituximab for pts with relapsed\/refractory chronic lymphocytic #leukaemia #CLL #lylcl","Results have been published on a study that we recruited 3 chronic lymphocytic patients to in Cornwall.","Idelalisib or placebo in combination with bendamustine and rituximab in R\/R chronic lymphocytic leukaemia","Adding Zydelig to BR for CLL #leukemia improved PFS by ~10 mo; rate of infections were 1.5x\u2b06 #study @TheLancetOncol"],"citation":{"abstract":"Bendamustine plus rituximab is a standard of care for the management of patients with relapsed or refractory chronic lymphocytic leukaemia. New therapies are needed to improve clinically relevant outcomes in these patients. We assessed the efficacy and safety of adding idelalisib, a first-in-class targeted phosphoinositide-3-kinase \u03b4 inhibitor, to bendamustine plus rituximab in this population.\nFor this international, multicentre, double-blind, placebo-controlled trial, adult patients (\u226518 years) with relapsed or refractory chronic lymphocytic leukaemia requiring treatment who had measurable lymphadenopathy by CT or MRI and disease progression within 36 months since their last previous therapy were enrolled. Patients were randomly assigned (1:1) by a central interactive web response system to receive bendamustine plus rituximab for a maximum of six cycles (bendamustine: 70 mg\/m(2) intravenously on days 1 and 2 for six 28-day cycles; rituximab: 375 mg\/m(2) on day 1 of cycle 1, and 500 mg\/m(2) on day 1 of cycles 2-6) in addition to either twice-daily oral idelalisib (150 mg) or placebo until disease progression or intolerable study drug-related toxicity. Randomisation was stratified by high-risk features (IGHV, del[17p], or TP53 mutation) and refractory versus relapsed disease. The primary endpoint was progression-free survival assessed by an independent review committee in the intention-to-treat population. This trial is ongoing and is registered with ClinicalTrials.gov, number NCT01569295.\nBetween June 26, 2012, and Aug 21, 2014, 416 patients were enrolled and randomly assigned to the idelalisib (n=207) and placebo (n=209) groups. At a median follow-up of 14 months (IQR 7-18), median progression-free survival was 20\u00b78 months (95% CI 16\u00b76-26\u00b74) in the idelalisib group and 11\u00b71 months (8\u00b79-11\u00b71) in the placebo group (hazard ratio [HR] 0\u00b733, 95% CI 0\u00b725-0\u00b744; p<0\u00b70001). The most frequent grade 3 or worse adverse events in the idelalisib group were neutropenia (124 [60%] of 207 patients) and febrile neutropenia (48 [23%]), whereas in the placebo group they were neutropenia (99 [47%] of 209) and thrombocytopenia (27 [13%]). An increased risk of infection was reported in the idelalisib group compared with the placebo group (grade \u22653 infections and infestations: 80 [39%] of 207 vs 52 [25%] of 209). Serious adverse events, including febrile neutropenia, pneumonia, and pyrexia, were more common in the idelalisib group (140 [68%] of 207 patients) than in the placebo group (92 [44%] of 209). Treatment-emergent adverse events leading to death occurred in 23 (11%) patients in the idelalisib group and 15 (7%) in the placebo group, including six deaths from infections in the idelalisib group and three from infections in the placebo group.\nIdelalisib in combination with bendamustine plus rituximab improved progression-free survival compared with bendamustine plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukaemia. However, careful attention needs to be paid to management of serious adverse events and infections associated with this regimen during treatment selection.\nGilead Sciences Inc.","altmetric_jid":"4f6fa4f73cf058f610002fd1","authors":["Zelenetz, Andrew D","Barrientos, Jacqueline C","Brown, Jennifer R","Coiffier, Bertrand","Delgado, Julio","Egyed, Mikl\u00f3s","Ghia, Paolo","Ill\u00e9s, \u00c1rp\u00e1d","Jurczak, Wojciech","Marlton, Paula","Montillo, Marco","Morschhauser, Franck","Pristupa, Alexander S","Robak, Tadeusz","Sharman, Jeff P","Simpson, David","Smolej, Luk\u00e1\u0161","Tausch, Eugen","Adewoye, Adeboye H","Dreiling, Lyndah K","Kim, Yeonhee","Stilgenbauer, Stephan","Hillmen, Peter","Andrew D Zelenetz","Jacqueline C Barrientos","Jennifer R Brown","Bertrand Coiffier","Julio Delgado","Mikl\u00f3s Egyed","Paolo Ghia","\u00c1rp\u00e1d Ill\u00e9s","Wojciech Jurczak","Paula Marlton","Marco Montillo","Franck Morschhauser","Alexander S Pristupa","Tadeusz Robak","Jeff P Sharman","David Simpson","Luk\u00e1\u0161 Smolej","Eugen Tausch","Adeboye H Adewoye","Lyndah K Dreiling","Yeonhee Kim","Stephan Stilgenbauer","Peter Hillmen"],"doi":"10.1016\/s1470-2045(16)30671-4","first_seen_on":"2017-01-28T05:23:45+00:00","funders":["niehs","nci"],"issns":["1470-2045","14702045","1474-5488"],"issue":"3","journal":"Lancet Oncology","last_mentioned_on":1504358104,"links":["http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(16)30671-4\/fulltext?rss=yes","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=3&redirect=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanonc%2Farticle%2FPIIS1470-2045%2816%2930671-4%2Ffulltext&code=lancet-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=8&redirect=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanonc%2Farticle%2FPIIS1470-2045%2816%2930671-4%2Ffulltext&code=lancet-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=1&redirect=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanonc%2Farticle%2FPIIS1470-2045%2816%2930671-4%2Fabstract&code=lancet-site","http:\/\/dx.doi.org\/10.1016\/S1470-2045(16)30671-4","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=3&redirect=http%3A%2F%2Fwww.thelancet.com%2Fpdfs%2Fjournals%2Flanonc%2FPIIS1470-2045%2816%2930671-4.pdf&code=lancet-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=7&redirect=http%3A%2F%2Fwww.thelancet.com%2Fpdfs%2Fjournals%2Flanonc%2FPIIS1470-2045%2816%2930671-4.pdf&code=lancet-site","http:\/\/www.thelancet.com\/pdfs\/journals\/lanonc\/PIIS1470-2045(16)30671-4.pdf","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=2&redirect=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanonc%2Farticle%2FPIIS1470-2045%2816%2930671-4%2Ffulltext%3Frss%3Dyes&code=lancet-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=3&redirect=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanonc%2Farticle%2FPIIS1470-2045%252816%252930671-4%2Ffulltext&code=lancet-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=2&redirect=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanonc%2Farticle%2FPIIS1470-2045%252816%252930671-4%2Ffulltext&code=lancet-site","http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045%2816%2930671-4\/fulltext#.WLm4Coj0xiU.twitter","http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(16)30671-4\/fulltext?elsca1=etoc","http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(16)30671-4\/fulltext","https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Lancet+Oncol+18:297-311,+2017"],"pdf_url":"http:\/\/www.thelancet.com\/article\/S1470204516306714\/pdf","pmid":"28139405","pubdate":"2017-01-01T00:00:00+00:00","publisher":"Elsevier BV","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"297","subjects":["neoplasms"],"title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial","type":"article","volume":"18","mendeley_url":"http:\/\/www.mendeley.com\/research\/idelalisib-placebo-combination-bendamustine-rituximab-patients-relapsed-refractory-chronic-lymphocyt-2"},"altmetric_score":{"score":37.6,"score_history":{"1y":37.6,"6m":14,"3m":14,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":37.6},"context_for_score":{"all":{"total_number_of_other_articles":8461697,"mean":7.1088157534769,"rank":251386,"this_scored_higher_than_pct":97,"this_scored_higher_than":8210251,"rank_type":"exact","sample_size":8461697,"percentile":97},"similar_age_3m":{"total_number_of_other_articles":283361,"mean":12.528617123094,"rank":15911,"this_scored_higher_than_pct":94,"this_scored_higher_than":267436,"rank_type":"exact","sample_size":283361,"percentile":94},"this_journal":{"total_number_of_other_articles":3630,"mean":18.725298429319,"rank":323,"this_scored_higher_than_pct":91,"this_scored_higher_than":3306,"rank_type":"exact","sample_size":3630,"percentile":91},"similar_age_this_journal_3m":{"total_number_of_other_articles":145,"mean":31.983055555556,"rank":25,"this_scored_higher_than_pct":82,"this_scored_higher_than":120,"rank_type":"exact","sample_size":145,"percentile":82}}},"demographics":{"poster_types":{"member_of_the_public":6,"researcher":1,"practitioner":6,"science_communicator":1},"users":{"twitter":{"cohorts":{"Members of the public":6,"Science communicators (journalists, bloggers, editors)":1,"Practitioners (doctors, other healthcare professionals)":6,"Scientists":1}},"mendeley":{"by_status":{"Professor > Associate Professor":2,"Researcher":3,"Student  > Doctoral Student":1,"Student  > Postgraduate":2,"Other":5,"Student  > Master":2,"Lecturer":1,"Professor":2},"by_discipline":{"Medicine and Dentistry":15,"Computer Science":1,"Mathematics":1,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"twitter":{"GB":4,"IE":1,"ES":2,"CA":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/GarbineLizeaga\/statuses\/825212683062476801","license":"gnip","citation_ids":[15903666],"posted_on":"2017-01-28T05:23:30+00:00","author":{"name":"Garbi\u00f1e Lizeaga","image":"https:\/\/pbs.twimg.com\/profile_images\/786651537573572608\/fOvQvTXd_normal.jpg","description":"FHyAP. OSI Donostialdea. De todo como en botica.","id_on_source":"GarbineLizeaga","tweeter_id":"2244183212","geo":{"lt":null,"ln":null},"followers":408},"tweet_id":"825212683062476801"},{"url":"http:\/\/twitter.com\/TheLancetOncol\/statuses\/826072733926752257","license":"gnip","citation_ids":[15903666],"posted_on":"2017-01-30T14:21:02+00:00","author":{"name":"The Lancet Oncology","url":"http:\/\/www.thelancet.com","image":"https:\/\/pbs.twimg.com\/profile_images\/441608748306423808\/qlozKasq_normal.jpeg","description":"The Lancet Oncology is the world-leading clinical oncology journal publishing high-quality, peer-reviewed research and reviews, comment, news, and Commissions.","id_on_source":"TheLancetOncol","tweeter_id":"50265238","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":12049},"tweet_id":"826072733926752257"},{"url":"http:\/\/twitter.com\/elhadialgerino\/statuses\/826074723910086657","license":"gnip","rt":["TheLancetOncol"],"citation_ids":[15903666],"posted_on":"2017-01-30T14:28:56+00:00","author":{"name":"el-hadi algerino","image":"https:\/\/pbs.twimg.com\/profile_images\/639357555274330113\/K8GuYqjE_normal.jpg","id_on_source":"elhadialgerino","tweeter_id":"3092485558","geo":{"lt":53,"ln":-8,"country":"IE"},"followers":36},"tweet_id":"826074723910086657"},{"url":"http:\/\/twitter.com\/ONKOSconsulting\/statuses\/826204221380915201","license":"gnip","rt":["TheLancetOncol"],"citation_ids":[15903666],"posted_on":"2017-01-30T23:03:31+00:00","author":{"name":"ONKOS Consulting","image":"https:\/\/pbs.twimg.com\/profile_images\/579978338049138688\/RqlopOAX_normal.png","id_on_source":"ONKOSconsulting","tweeter_id":"3107537152","geo":{"lt":null,"ln":null},"followers":29},"tweet_id":"826204221380915201"},{"url":"http:\/\/twitter.com\/duchongle\/statuses\/826207977870880769","license":"gnip","rt":["TheLancetOncol"],"citation_ids":[15903666],"posted_on":"2017-01-30T23:18:26+00:00","author":{"name":"Duc Le","image":"https:\/\/pbs.twimg.com\/profile_images\/570700950688387072\/7FE-N66V_normal.jpeg","id_on_source":"duchongle","tweeter_id":"58558418","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":153},"tweet_id":"826207977870880769"},{"url":"http:\/\/twitter.com\/ClinicalBriefs\/statuses\/828697356916944896","license":"gnip","citation_ids":[15903666],"posted_on":"2017-02-06T20:10:20+00:00","author":{"name":"Holden Caulfield PhD","url":"http:\/\/Clinical-Briefs.com","image":"https:\/\/pbs.twimg.com\/profile_images\/779016881428688897\/TFyQGGxg_normal.jpg","description":"Indep writer @ClinicalBriefs: Medical insights, simplified\u2122. Follow for news on medical research and policy. Opinions are my own.","id_on_source":"ClinicalBriefs","tweeter_id":"3810014352","geo":{"lt":null,"ln":null},"followers":355},"tweet_id":"828697356916944896"},{"url":"http:\/\/twitter.com\/NHSResCornwall\/statuses\/834009978834919424","license":"gnip","citation_ids":[15903666],"posted_on":"2017-02-21T12:00:48+00:00","author":{"name":"Cornwall Research","image":"https:\/\/pbs.twimg.com\/profile_images\/613713281455386624\/maJjEMuQ_normal.jpg","description":"News and information about NHS Research in Cornwall.","id_on_source":"NHSResCornwall","tweeter_id":"3318513891","geo":{"lt":50.26526,"ln":-5.05436,"country":"GB"},"followers":81},"tweet_id":"834009978834919424"},{"url":"http:\/\/twitter.com\/FarmaOnco\/statuses\/837173867655344129","license":"gnip","citation_ids":[15903666],"posted_on":"2017-03-02T05:32:58+00:00","author":{"name":"FarmaOnco","image":"https:\/\/pbs.twimg.com\/profile_images\/2930931336\/c5ed1efcf9ddf36d4803c1ab88604f4f_normal.jpeg","description":"Farmac\u00e9utica hospitalaria que intenta mantenerse al d\u00eda en onco, hemato y otras cosas","id_on_source":"FarmaOnco","tweeter_id":"917639060","geo":{"lt":null,"ln":null},"followers":1686},"tweet_id":"837173867655344129"},{"url":"http:\/\/twitter.com\/hematosantpau\/statuses\/837181182081183744","license":"gnip","rt":["FarmaOnco"],"citation_ids":[15903666],"posted_on":"2017-03-02T06:02:02+00:00","author":{"name":"Hematolog\u00eda SantPau","url":"http:\/\/www.santpau.cat\/ca\/web\/public\/hc-inici","image":"https:\/\/pbs.twimg.com\/profile_images\/753318144626847745\/oK2mXlI4_normal.jpg","description":"Hospital de la Santa Creu i Sant Pau","id_on_source":"hematosantpau","tweeter_id":"721616184731426816","geo":{"lt":41.38879,"ln":2.15899,"country":"ES"},"followers":376},"tweet_id":"837181182081183744"},{"url":"http:\/\/twitter.com\/Sidnavigare\/statuses\/837734166120771584","license":"gnip","citation_ids":[15903666],"posted_on":"2017-03-03T18:39:24+00:00","author":{"name":"Francesc Bosch","image":"https:\/\/pbs.twimg.com\/profile_images\/723135911500873728\/-6EJ9Xmn_normal.jpg","description":"Hematologist. Head of Department of Hematology, Hospital Vall d'Hebron; Chair of the Spanish Group of CLL (GELLC)","id_on_source":"Sidnavigare","tweeter_id":"723134666153168897","geo":{"lt":41.38879,"ln":2.15899,"country":"ES"},"followers":169},"tweet_id":"837734166120771584"},{"url":"http:\/\/twitter.com\/SCTNB\/statuses\/837784497835892737","license":"gnip","rt":["Sidnavigare"],"citation_ids":[15903666],"posted_on":"2017-03-03T21:59:24+00:00","author":{"name":"Dr T. Comeau , MD","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000365246082\/373bc9bced36e8f90f0d52d727fc6b34_normal.jpeg","description":"Director New Brunswick Stem Cell Transplant Program ; SCT Physician ; #hematology: #leukemia, #MDS, #lymphoma, #mmsm , #apheresis, #bmtsm , #immunotherapy","id_on_source":"SCTNB","tweeter_id":"314498013","geo":{"lt":60.10867,"ln":-113.64258,"country":"CA"},"followers":1170},"tweet_id":"837784497835892737"},{"url":"http:\/\/twitter.com\/queizan\/statuses\/837792471249743872","license":"gnip","rt":["Sidnavigare"],"citation_ids":[15903666],"posted_on":"2017-03-03T22:31:05+00:00","author":{"name":"Dr. Jos\u00e9 A. Queiz\u00e1n","image":"https:\/\/pbs.twimg.com\/profile_images\/805313113016799232\/jBSTAjA7_normal.jpg","description":"Medico Especialista en Hematologia y Hemoterapia","id_on_source":"queizan","tweeter_id":"2334315479","geo":{"lt":null,"ln":null},"followers":403},"tweet_id":"837792471249743872"},{"url":"http:\/\/twitter.com\/MartaCrespoHEM\/statuses\/837795216996380672","license":"gnip","rt":["Sidnavigare"],"citation_ids":[15903666],"posted_on":"2017-03-03T22:41:59+00:00","author":{"name":"Marta Crespo","url":"http:\/\/www.vhir.org\/gr\/hematology","image":"https:\/\/pbs.twimg.com\/profile_images\/810871351506518018\/uFTXQz6K_normal.jpg","description":"Research Scientist at the Experimental Hematology lab in Vall d\u2019Hebron Institut de Recerca (Barcelona) @VHIR_","id_on_source":"MartaCrespoHEM","tweeter_id":"2548096447","geo":{"lt":null,"ln":null},"followers":184},"tweet_id":"837795216996380672"},{"url":"http:\/\/twitter.com\/lymphomahub\/statuses\/838689081336938496","license":"gnip","rt":["Sidnavigare"],"citation_ids":[15903666],"posted_on":"2017-03-06T09:53:53+00:00","author":{"name":"Lymphoma Hub","url":"http:\/\/www.lymphomahub.com","image":"https:\/\/pbs.twimg.com\/profile_images\/816644675025207296\/mwybWyru_normal.jpg","description":"The LH is an online resource dedicated to sharing lymphoma\/CLL latest medical information  within the community hematologists, oncologists and hem-oncologists","id_on_source":"lymphomahub","tweeter_id":"1582593798","geo":{"lt":54.75844,"ln":-2.69531,"country":"GB"},"followers":1895},"tweet_id":"838689081336938496"}],"news":[{"title":"Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia","url":"http:\/\/www.oncologynurseadvisor.com\/idelalisib-to-bendamustine-plus-rituximab-increase-pfs-in-patients-with-rr-chronic-lymphocytic-leukemia\/article\/638153\/","license":"public","citation_ids":[15903666],"posted_on":"2017-02-15T16:00:00+00:00","summary":"The addition of idelalisib to bendamustine plus rituximab significantly increased progression-free survival (PFS) compared to bendamustine plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).1 Standard\u2026","author":{"name":"Oncology Nurse Advisor ","url":"http:\/\/www.oncologynurseadvisor.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/276\/normal\/Screen_Shot_2014-11-20_at_11.19.42.png?1416482413"}},{"title":"Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia","url":"http:\/\/ct.moreover.com\/?a=29598893294&p=1pl&v=1&x=-pTLdaLQaSLcG7rzoA4u9w","license":"public","citation_ids":[15903666],"posted_on":"2017-02-15T16:00:00+00:00","summary":"The addition of idelalisib to bendamustine plus rituximab significantly increased progression-free survival (PFS) compared to bendamustine plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).1 Standard\u2026","author":{"name":"Oncology Nurse Advisor ","url":"http:\/\/www.oncologynurseadvisor.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/276\/normal\/Screen_Shot_2014-11-20_at_11.19.42.png?1416482413"}},{"title":"CLL boost in PFS came at high cost in side effects","url":"http:\/\/ct.moreover.com\/?a=29833567429&p=1pl&v=1&x=w5UCqMOFlXC6ZGdJCvVqeQ","license":"public","citation_ids":[15903666,17149731],"posted_on":"2017-03-08T17:43:47+00:00","summary":"FROM THE LANCET ONCOLOGY Add-on idelalisib boosted the progression-free survival (PFS) of patients with relapsed and refractory chronic lymphocytic leukemia by over 9 months in a double-blind, placebo-controlled trial of 416 participants.","author":{"name":"PM 360","url":"http:\/\/www.pm360online.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/739\/normal\/Screen_Shot_2016-02-02_at_17.08.15.png?1454432906"}},{"title":"Adding Idelalisib to Bendamustine\/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","url":"http:\/\/ct.moreover.com\/?a=30657913141&p=1pl&v=1&x=luMKWgzzGDfKOF8J3uCPcg","license":"public","citation_ids":[15903666],"posted_on":"2017-05-22T22:50:35+00:00","summary":"By Matthew Stenger Posted: 2\/8\/2017 9:33:55 AM Last Updated: 2\/8\/2017 9:33:55 AM Tweet this page Advertisement Adding idelalisib to bendamustine\/rituximab improved progression-free and overall survival in patients with relapsed or refractory CLL.","author":{"name":"The ASCO Post","url":"http:\/\/www.ascopost.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/496\/normal\/Screen_Shot_2016-02-03_at_09.24.05.png?1454491455"}},{"title":"Idelalisib in Resistant CLL: Benefit Shown, Questions Remain","url":"http:\/\/ct.moreover.com\/?a=31162225140&p=1pl&v=1&x=fQQ4JvNbL2AuadWvnDJobg","license":"public","citation_ids":[15903666,4844299,4605509,5057943,4484178],"posted_on":"2017-07-10T14:43:42+00:00","summary":"Advertisement As reported in The Lancet Oncology by Dr. Andrew Zelenetz and colleagues and reviewed in this issue of The ASCO Post, an international phase III trial in 416 patients with refractory or recurrent chronic lymphocytic leukemia (CLL\u2026","author":{"name":"The ASCO Post","url":"http:\/\/www.ascopost.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/496\/normal\/Screen_Shot_2016-02-03_at_09.24.05.png?1454491455"}},{"title":"Adding Idelalisib to Bendamustine\/Rituximab in Relapsed\/Refractory CLL","url":"http:\/\/ct.moreover.com\/?a=31162224939&p=1pl&v=1&x=B_pWQ9aezdvfSDpDh_76Kg","license":"public","citation_ids":[15903666],"posted_on":"2017-07-10T14:43:40+00:00","summary":"Advertisement As reported by Andrew D. Zelenetz, MD, of Memorial Sloan Kettering Cancer Center, and colleagues in The Lancet Oncology, interim analysis of a phase III trial has shown the superiority of adding the phosphoinositide-3-kinase \u03b4\u2026","author":{"name":"The ASCO Post","url":"http:\/\/www.ascopost.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/496\/normal\/Screen_Shot_2016-02-03_at_09.24.05.png?1454491455"}},{"title":"Leucemia linfatica cronica, aggiunta di idelalisib allo standard of care migliora la sopravvivenza nei pazienti ricaduti refrattari","url":"http:\/\/www.pharmastar.it\/index.html?cat=22&id=24690","license":"public","citation_ids":[15903666,21604634],"posted_on":"2017-08-27T00:00:00+00:00","summary":"Nei pazienti con leucemia linfatica cronica recidivata\/refrattaria, il trattamento con idelalisib in combinazione con bendamustina e rituximab migliora la sopravvivenza libera da progressione (PFS) rispetto allo standard of care, che \u00e8 in questo\u2026","author":{"name":"Pharmastar Italy","url":"http:\/\/pharmastar.it\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/289\/normal\/Screen_Shot_2014-11-27_at_11.59.12.png?1417089569"}},{"title":"Ca al seno, bisfosfonati non associati a una riduzione del rischio","url":"http:\/\/www.pharmastar.it\/index.html?cat=22&id=24691","license":"public","citation_ids":[21918841,15903666,21604634,21918841],"posted_on":"2017-08-27T00:00:00+00:00","summary":"I bisfosfonati sono farmaci di provata efficacia per la prevenzione dell\u2019osteoporosi e delle fratture da fragilit\u00e0, ma pare non si possa dire altrettanto per la riduzione del rischio di tumore al seno, propriet\u00e0 che \u00e8 stata loro pi\u00f9 volte attribuita.","author":{"name":"Pharmastar Italy","url":"http:\/\/pharmastar.it\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/289\/normal\/Screen_Shot_2014-11-27_at_11.59.12.png?1417089569"}},{"title":"Ca al seno, bisfosfonati non associati a una riduzione del rischio","url":"http:\/\/ct.moreover.com\/?a=31709955627&p=1pl&v=1&x=06QO-0MBxZ0mM4QLQsGvjg","license":"public","citation_ids":[21918841,15903666,21604634,21918841],"posted_on":"2017-09-02T13:15:04+00:00","summary":"I bisfosfonati sono farmaci di provata efficacia per la prevenzione dell\u2019osteoporosi e delle fratture da fragilit\u00e0, ma pare non si possa dire altrettanto per la riduzione del rischio di tumore al seno, propriet\u00e0 che \u00e8 stata loro pi\u00f9 volte attribuita.","author":{"name":"Pharmastar Italy","url":"http:\/\/pharmastar.it\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/289\/normal\/Screen_Shot_2014-11-27_at_11.59.12.png?1417089569"}},{"title":"Leucemia linfatica cronica, aggiunta di idelalisib allo standard of care migliora la sopravvivenza nei pazienti ricaduti refrattari","url":"http:\/\/ct.moreover.com\/?a=31709955638&p=1pl&v=1&x=dEeANI41eYd4CSmAtsCiyw","license":"public","citation_ids":[15903666,21604634],"posted_on":"2017-09-02T13:15:04+00:00","summary":"Nei pazienti con leucemia linfatica cronica recidivata\/refrattaria, il trattamento con idelalisib in combinazione con bendamustina e rituximab migliora la sopravvivenza libera da progressione (PFS) rispetto allo standard of care, che \u00e8 in questo\u2026","author":{"name":"Pharmastar Italy","url":"http:\/\/pharmastar.it\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/289\/normal\/Screen_Shot_2014-11-27_at_11.59.12.png?1417089569"}}],"facebook":[{"title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1374748212598225&id=480798328659889","license":"public","citation_ids":[15903666],"posted_on":"2017-02-21T11:55:04+00:00","summary":"Results have been published on a study that we recruited 3 chronic lymphocytic patients to in Cornwall. leukaemiahttp:\/\/www.thelancet.com\/pdfs\/journals\/lanonc\/PIIS1470-2045(16)30671-4.pdf","author":{"name":"NHS Research in Cornwall","url":"https:\/\/www.facebook.com\/480798328659889","facebook_wall_name":"NHS Research in Cornwall","image":"https:\/\/graph.facebook.com\/480798328659889\/picture","id_on_source":"480798328659889"}}]}}